Abstract
Objective of this study is to retrospectively compare the third generation anti-cyclic citrullinated peptide (anti-CCP3) test with the second generation (anti-CCP2) assay as markers of disease activity and predictors of clinical response in rheumatoid arthritis (RA) patients treated with TNF-alpha blocking agents. This study was performed in 42 RA patients treated either with infliximab (n = 11), etanercept (n = 7) or adalimumab (n = 24). Serum anti-CCP3 and anti-CCP2 levels were tested before and 6 months after starting a TNF-alpha blocking treatment using commercially available ELISA kits. Anti-CCP3 and anti-CCP2 antibody levels did not significantly change after 6 months of TNF-alpha blocking treatment. Furthermore, neither anti-CCP3 nor anti-CCP2 was useful to predict anti-TNF-alpha treatment response using receiving operating characteristic curve and logistic regression analyses. Both anti-CCP3 and anti-CCP2 are not differentially influenced by TNF-alpha blocking agents in RA patients and failed to predict anti-TNF-alpha treatment response.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adalimumab
-
Antibodies, Anti-Idiotypic / blood
-
Antibodies, Anti-Idiotypic / immunology*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Arthritis, Rheumatoid / physiopathology
-
Autoantibodies / blood
-
Autoantibodies / immunology
-
Disease Progression
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / therapeutic use
-
Infliximab
-
Male
-
Middle Aged
-
Peptides, Cyclic / blood
-
Peptides, Cyclic / immunology*
-
Predictive Value of Tests
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Retrospective Studies
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Anti-Idiotypic
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Autoantibodies
-
Immunoglobulin G
-
Peptides, Cyclic
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
cyclic citrullinated peptide
-
Infliximab
-
Adalimumab
-
Etanercept